The global market for weight-control products of all types is forecast to hit $53 billion in just five years, and several companies are primed to profit. More
RHHBY
Recent Articles
Feel Safe Scooping Up Swiss Stocks
There's a lot to like about Switzerland as an investment haven. It's not a perfect environment, but a number of Swiss stocks look promising right now. More
Forecast: Top 15 Pharma Companies in 2018
Novartis will be No. 1, and just one U.S. firm will remain among the top 5, according to EvalutePharma's research. More
Cue the Biotech M&A Attack!
A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road. More
3 New Biotech Buys for Your Portfolio
Three new biotech buys lead the way for additions to your portfolio as we head into April. More
Analysts Run the Apple Asylum — Tuesday’s IP Market Recap
Price targets keep climbing to the moon: $715, $910 -- even $1,001. More
Here Comes a Bidding War for Amylin
Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share. More
